diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/DM13184diaendo-13184Research ArticleОригинальные исследованияOriginal StudiesМесто гликлазида МВ в современных стратегиях лечения пациентов с сахарным диабетом 2 типаThe place of gliclazide MB in modern treatment strategies for patients with type 2 diabetes mellitushttps://orcid.org/0000-0001-9390-1200ПетунинаН. А.PetuninaN. A.

Петунина Нина Александровна - д.м.н., профессор, член-корреспондент РАН.

Москва

Nina A. Petunina - PhD, Professor, Сorr. Member of the RAS.

Moscow

napetunina@mail.ruhttps://orcid.org/0000-0002-0202-1257МартиросянН. С.MartirosianN. S.

Мартиросян Нарине Степановна - к.м.н.

119435, Москва, ул. Большая Пироговская, д. 2, стр. 4

Narine S. Martirosian - PhD.

2/4, Bolshaya Pirogovskaya Street, 119991 Moscow

narinarine@list.ruhttps://orcid.org/0000-0001-7025-8427ГончароваЕ. В.GoncharovaE. V.

Гончарова Екатерина Валерьевна - к.м.н.

Москва

Ekaterina V. Goncharova - PhD.

Moscow

goncharova_ev@list.ruhttps://orcid.org/0000-0001-8007-9721ТельноваМ. Э.TelnovaM. E.

Тельнова Милена Эдуардовна - к.м.н.

Москва

Milena E. Telnova - PhD.

Moscow

milena.telnova@mail.ruhttps://orcid.org/0000-0001-7923-4894КузинаИ. А.KuzinaI. A.

Кузина Ирина Александровна

Москва

Irina A. Kuzina

Moscow

mia986@mail.ruhttps://orcid.org/0000-0001-7658-7053ЩетининаА. О.ShchetininaA. O.

Щетинина Анна Олеговна - к.м.н.

Москва

Anna O. Shchetinina - PhD.

Moscow

ivaninskaya@mail.ruhttps://orcid.org/0009-0004-7026-4471ЭльмурзаеваЭ. А.ElmurzaevaE. A.

Эльмурзаева Эльмира Акрамовна

Москва

Elmira A. Elmurzaeva

Moscow

elmi.rami@yandex.ruСеченовский УниверситетРоссияI.M. Sechenov First Moscow State Medical UniversityRussian Federation202404092024274368375Copyright © Петунина Н.А., Мартиросян Н.С., Гончарова Е.В., Тельнова М.Э., Кузина И.А., Щетинина А.О., Эльмурзаева Э.А., 20242024Петунина Н.А., Мартиросян Н.С., Гончарова Е.В., Тельнова М.Э., Кузина И.А., Щетинина А.О., Эльмурзаева Э.А.Petunina N.A., Martirosian N.S., Goncharova E.V., Telnova M.E., Kuzina I.A., Shchetinina A.O., Elmurzaeva E.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/13184

Производные сульфонилмочевины (ПСМ) являются эффективными классом пероральных сахароснижающих препаратов, более 70 лет использующихся в клинической практике. Несмотря на общий механизм действия, для представителей класса характерны значимые внутриклассовые отличия по сахароснижающей активности, безопасности и наличию внепанкреатических эффектов. В данном обзоре рассматриваются особенности гликлазида с модифицированным высвобождением (MВ), его отличия от других представителей класса ПСМ и место в современных рекомендациях по терапии сахарного диабета 2 типа (СД2). Гликлазид МВ относится к современным ПСМ 2 поколения с высокой сахароснижающей активностью, низким риском гипогликемии вследствие обратимого связывания с рецептором SUR1 и отсутствием влияния на Epac2 путь, в целом нейтральным влиянием на вес, имеет доказанные нефропротективные свойства и благоприятный профиль сердечно-сосудистой безопасности, что позволяет выделять его среди представителей класса ПСМ. Международные и национальные клинические рекомендации отмечают место ПСМ при необходимости интенсификации сахароснижающей терапии и гликемического контроля у пациентов с СД2.

Sulfonylurea (SU) are an effective class of oral hypoglycemic drugs that have been used in clinical practice for more than 70 years. Despite the common mechanism of action, members of the class have significant intraclass differences in hypoglycemic activity, safety, and the presence of extrapancreatic effects. This review examines the features of gliclazide modified release (MR), its differences from other representatives of the SU and its place in modern recommendations for the treatment of type 2 diabetes mellitus. Gliclazide MR belongs to the modern 2nd generation SU with high hypoglycemic activity, low risk of hypoglycemia due to reversible binding to the SUR1 receptor and no effect on the Epac2 pathway, generally neutral effect on weight, proven nephroprotective properties and cardiovascular safety, which makes it possible to highlight it among representatives of the SU class. International and national clinical guidelines indicate the place of SU when it is necessary to intensify glucose-lowering therapy and glycemic control in patients with type 2 diabetes mellitus.

гликлазидсахарный диабет 2 типасульфонилмочевинанефропротекцияdiabetes mellitussulfonylureasgliclazidenephroprotectionРабота выполнена по инициативе авторов без привлечения финансированияReferencesДедов И.И., Шестакова М.В., Викулова О.К., и др. Сахарный диабет в Российской Федерации: динамика эпидемиологических показателей по данным Федерального регистра сахарного диабета за период 2010–2022 гг. // Сахарный диабет. — 2023. — Т. 26. — №2. — С. 104–123. doi: https://doi.org/10.14341/DM13035Dedov II, Shestakova MV, Vikulova OK, et al. Diabetes mellitus in the Russian Federation: dynamics of epidemiological indicators according to the Federal Register of Diabetes Mellitus for the period 2010–2022. Diabetes Mellitus. 2023;26(2):104-123. (In Russ.). doi: https://doi.org/10.14341/DM13035Paul SK, Klein K, Thorsted BL, et al. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovasc Diabetol. 2015;14:100. doi: https://doi.org/10.1186/s12933-015-0260-xPaul SK, Klein K, Thorsted BL, et al. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovasc Diabetol. 2015;14:100. doi: https://doi.org/10.1186/s12933-015-0260-xLind M, Imberg H, Coleman RL, et al. Historical HbA1c Values May Explain the Type 2 Diabetes Legacy Effect: UKPDS 88. Diabetes Care. 2021;44(10):2231–7. doi: https://doi.org/10.2337/dc20-2439Lind M, Imberg H, Coleman RL, et al. Historical HbA1c Values May Explain the Type 2 Diabetes Legacy Effect: UKPDS 88. Diabetes Care. 2021;44(10):2231–7. doi: https://doi.org/10.2337/dc20-2439Wang H, Cordiner RLM, Huang Y, et al.; Scottish Diabetes Research Network Epidemiology Group. Cardiovascular Safety in Type 2 Diabetes With Sulfonylureas as Second-line Drugs: A Nationwide Population-Based Comparative Safety Study. Diabetes Care. 2023;46(5):967-977. doi: https://doi.org/10.2337/dc22-1238Wang H, Cordiner RLM, Huang Y, et al.; Scottish Diabetes Research Network Epidemiology Group. Cardiovascular Safety in Type 2 Diabetes With Sulfonylureas as Second-line Drugs: A Nationwide Population-Based Comparative Safety Study. Diabetes Care. 2023;46(5):967-977. doi: https://doi.org/10.2337/dc22-1238Laiteerapong N, Ham SA, Gao Y, et al. The Legacy Effect in Type 2 Diabetes: Impact of Early Glycemic Control on Future Complications (The Diabetes & Aging Study). Diabetes Care. 2019;42(3):416-426. doi: https://doi.org/10.2337/dc17-1144Laiteerapong N, Ham SA, Gao Y, et al. The Legacy Effect in Type 2 Diabetes: Impact of Early Glycemic Control on Future Complications (The Diabetes & Aging Study). Diabetes Care. 2019;42(3):416-426. doi: https://doi.org/10.2337/dc17-1144Петунина Н.А., Гончарова Е.В., Кузина И.А., Недосугова Л.В., и др. Роль пиоглитазона в борьбе с инсулинорезистентностью, атеросклерозом, сердечно-сосудистыми заболеваниями и неалкогольной жировой болезнью печени // Сахарный диабет. — 2022. — Т. 25. — №5. — 504-513. doi: https://doi.org/10.14341/DM12859Petunina NA, Goncharova EV, Kuzina IA, Nedosugova LV. et al. The role of pioglitazone in the fight against insulin resistance, atherosclerosis, cardiovascular disease, and non-alcoholic fatty liver disease. Diabetes mellitus. 2022;25(5):504-513. (In Russ.). doi: https://doi.org/10.14341/DM12859Дедов И.И., Шестакова М.В., Майоров А.Ю., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 11-й вып. Сахарный диабет. — 2023. — Т. 26. — №2S. — С. 1–157. doi: https://doi.org/10.14341/DM13042Dedov II, Shestakova MV, Mayorov AYu, et al. Standards of specialized diabetes care. Edited by Dedov II, Shestakova MV, Mayorov AYu. 10th edition. Diabetes mellitus. 2021;24(1S):1-148. (In Russ.) doi: https://doi.org/10.14341/DM13042Qian D, Zhang T, Tan X, et al. Comparison of antidiabetic drugs added to sulfonylurea monotherapy in patients with type 2 diabetes mellitus: A network meta-analysis. PLoS One. 2018;13(8):e0202563. doi: https://doi.org/10.1371/journal.pone.0202563Qian D, Zhang T, Tan X, et al. Comparison of antidiabetic drugs added to sulfonylurea monotherapy in patients with type 2 diabetes mellitus: A network meta-analysis. PLoS One. 2018;13(8):e0202563. doi: https://doi.org/10.1371/journal.pone.0202563Huang X, Zhou Y, Tang H, et al. Differential metabolic network construction for personalized medicine: Study of type 2 diabetes mellitus patients’ response to gliclazide-modified-release-treated. J Biomed Inform. 2021;118:103796. doi: https://doi.org/10.1016/j.jbi.2021.103796Huang X, Zhou Y, Tang H, et al. Differential metabolic network construction for personalized medicine: Study of type 2 diabetes mellitus patients’ response to gliclazide-modified-release-treated. J Biomed Inform. 2021;118:103796. doi: https://doi.org/10.1016/j.jbi.2021.103796Sola D, Rossi L, Schianca GP, et al. Sulfonylureas and their use in clinical practice. Arch. Med. Sci. 2015;11(4):840–848. doi: https://doi.org/10.5114/aoms.2015.53304Sola D, Rossi L, Schianca GP, et al. Sulfonylureas and their use in clinical practice. Arch. Med. Sci. 2015;11(4):840–848. doi: https://doi.org/10.5114/aoms.2015.53304Seino S, Miki T. Physiological and pathophysiological roles of ATP-sensitive K+ channels. Prog Biophys Mol Biol. 2003;81(2):133-176. doi: https://doi.org/10.1016/s0079-6107(02)00053-6Seino S, Miki T. Physiological and pathophysiological roles of ATP-sensitive K+ channels. Prog Biophys Mol Biol. 2003;81(2):133-176. doi: https://doi.org/10.1016/s0079-6107(02)00053-6Петунина Н.А., Трухина Л.В., Гончарова Е.В. Преимущества интенсифицированного гликемического контроля: результаты исследований ADVANCE и ADVANCE-ON // Эффективная фармакотерапия. — 2015. — №7. — C. 12-16.Petunina NA, Trukhina LV, Goncharova EV. Advantages of Intensified Glycemic Control: Results of ADVANCE and ADVANCE-ON Studies. Effectivnaya farmakoterapiya. 2015;7:12-16. (In Russ.).Sugawara K, Shibasaki T, Takahashi H, Seino S. Structure and functional roles of Epac2 (Rapgef4). Gene. 2016;575(2):577-583. doi: https://doi.org/10.1016/j.gene.2015.09.029Sugawara K, Shibasaki T, Takahashi H, Seino S. Structure and functional roles of Epac2 (Rapgef4). Gene. 2016;575(2):577-583. doi: https://doi.org/10.1016/j.gene.2015.09.029Desfaits AC, Serri O, Renier G. Normalization of plasma lipid peroxides, monocyte adhesion, and tumor necrosis factor-alpha production in NIDDM patients after gliclazide treatment. Diabetes Care. 1998;21(4):487-93. doi: https://doi.org/10.2337/diacare.21.4.487Desfaits AC, Serri O, Renier G. Normalization of plasma lipid peroxides, monocyte adhesion, and tumor necrosis factor-alpha production in NIDDM patients after gliclazide treatment. Diabetes Care. 1998;21(4):487-93. doi: https://doi.org/10.2337/diacare.21.4.487Desfaits AC, Serri O, Renier G. Gliclazide reduces the induction of human monocyte adhesion to endothelial cells by glycated albumin. Diabetes, Obes Metab. 1999;1(2):113-120. doi: https://doi.org/10.1046/j.1463-1326.1999.00012.xDesfaits AC, Serri O, Renier G. Gliclazide reduces the induction of human monocyte adhesion to endothelial cells by glycated albumin. Diabetes, Obes Metab. 1999;1(2):113-120. doi: https://doi.org/10.1046/j.1463-1326.1999.00012.xA Räkel, G Renier, A Roussin, et al. Beneficial effects of gliclazide modified release compared with glibenclamide on endothelial activation and low-grade inflammation in patients with type 2 diabetes. Diabetes Obes Metab. 2007;9(1):127-9. doi: https://doi.org/10.1111/j.1463-1326.2006.00571.xA Räkel, G Renier, A Roussin, et al. Beneficial effects of gliclazide modified release compared with glibenclamide on endothelial activation and low-grade inflammation in patients with type 2 diabetes. Diabetes Obes Metab. 2007;9(1):127-9. doi: https://doi.org/10.1111/j.1463-1326.2006.00571.xZu Zhi Fu, Tang Yan, Yu-Ju Chen, Ji Quang Sang. Thromboxane/prostacyclin balance in type II diabetes: Gliclazide effects. Metabolism. 1992;41(5):33-35. doi: https://doi.org/10.1016/0026-0495(92)90092-OZu Zhi Fu, Tang Yan, Yu-Ju Chen, Ji Quang Sang. Thromboxane/prostacyclin balance in type II diabetes: Gliclazide effects. Metabolism. 1992;41(5):33-35. doi: https://doi.org/10.1016/0026-0495(92)90092-OKimura T, Takagi H, Suzuma K, et al. Comparisons between the beneficial effects of different sulphonylurea treatments on ischemia-induced retinal neovascularization. Free Radic Biol Med. 2007;43(3):454-461. doi: https://doi.org/10.1016/j.freeradbiomed.2007.04.030Kimura T, Takagi H, Suzuma K, et al. Comparisons between the beneficial effects of different sulphonylurea treatments on ischemia-induced retinal neovascularization. Free Radic Biol Med. 2007;43(3):454-461. doi: https://doi.org/10.1016/j.freeradbiomed.2007.04.030Мкртумян А.М., Духанин А.С. «Дорожная карта» препарата Диабетон МВ // Эффективная фармакотерапия. — 2019. — Т. 15. — №12. — С. 28–38. doi: https://doi.org/10.33978/2307-3586-2019-15-12-28-38Mkrtumyan AM, Dukhanin AS. ‘Road Map’ of the Drug Diabeton MR. Effectivnaya farmakoterapiya. 2019;15(12):28–38. (In Russ.) doi: https://doi.org/10.33978/2307-3586-2019-15-12-28-38Sena CM, Louro T, Matafome P, et al. Antioxidant and vascular effects of gliclazide in type 2 diabetic rats fed high-fat diet. Physiol Res. 2009;58(2):203-209. doi: https://doi.org/10.33549/physiolres.931480Sena CM, Louro T, Matafome P, et al. Antioxidant and vascular effects of gliclazide in type 2 diabetic rats fed high-fat diet. Physiol Res. 2009;58(2):203-209. doi: https://doi.org/10.33549/physiolres.931480Cordiner RLM, Mari A, Tura A, Pearson ER. The Impact of Low-dose Gliclazide on the Incretin Effect and Indices of Beta-cell Function. J Clin Endocrinol Metab. 2021;106(7):2036-2046. doi: https://doi.org/10.1210/clinem/dgab151Cordiner RLM, Mari A, Tura A, Pearson ER. The Impact of Low-dose Gliclazide on the Incretin Effect and Indices of Beta-cell Function. J Clin Endocrinol Metab. 2021;106(7):2036-2046. doi: https://doi.org/10.1210/clinem/dgab151Satoh J, Takahashi K, Takizawa Y, et al. Secondary sulfonylurea failure: comparison of period until insulin treatment between diabetic patients treated with gliclazide and glibenclamide. Diabetes Res Clin Pract. 2005;70(3):291-7. doi: https://doi.org/10.1016/j.diabres.2005.04.002Satoh J, Takahashi K, Takizawa Y, et al. Secondary sulfonylurea failure: comparison of period until insulin treatment between diabetic patients treated with gliclazide and glibenclamide. Diabetes Res Clin Pract. 2005;70(3):291-7. doi: https://doi.org/10.1016/j.diabres.2005.04.002University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. Diabetes. 1970;19(2):747-830University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. Diabetes. 1970;19(2):747-830Evans JM, Ogston SA, Emslie-Smith A, Morris AD. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia. 2006;49:930-36. doi: https://doi.org/10.1007/s00125-006-0176-9Evans JM, Ogston SA, Emslie-Smith A, Morris AD. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia. 2006;49:930-36. doi: https://doi.org/10.1007/s00125-006-0176-9Pantalone KM, Kattan MW, Yu C, et al. The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis. Diabetes Care. 2010;33:1224-29. doi: https://doi.org/10.2337/dc10-0017Pantalone KM, Kattan MW, Yu C, et al. The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis. Diabetes Care. 2010;33:1224-29. doi: https://doi.org/10.2337/dc10-0017Klepzig H, Kober G, Matter C, et al. Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. EurHeart. 1999;20:439-46. doi: https://doi.org/10.1053/euhj.1998.1242Klepzig H, Kober G, Matter C, et al. Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. EurHeart. 1999;20:439-46. doi: https://doi.org/10.1053/euhj.1998.1242Nordin C. The proarrhythmic effect of hypoglycemia: evidence for increased risk from ischemia and bradycardia. Acta Diabetol. 2014;51:5-14. doi: https://doi.org/10.1007/s00592-013-0528-0Nordin C. The proarrhythmic effect of hypoglycemia: evidence for increased risk from ischemia and bradycardia. Acta Diabetol. 2014;51:5-14. doi: https://doi.org/10.1007/s00592-013-0528-0Simpson SH, Lee J, Choi S, Vandermeer B, Abdelmoneim AS, Featherstone TR. Mortality risk among sulfonylureas: a systematic review and network meta-analysis. Lancet Diabetes Endocrinol. 2015;3(1):43-51. doi: https://doi.org/10.1016/S2213-8587(14)70213-XSimpson SH, Lee J, Choi S, Vandermeer B, Abdelmoneim AS, Featherstone TR. Mortality risk among sulfonylureas: a systematic review and network meta-analysis. Lancet Diabetes Endocrinol. 2015;3(1):43-51. doi: https://doi.org/10.1016/S2213-8587(14)70213-XZoungas S, Chalmers J, Kengne AP, et al. The efficacy of lowering glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial. Diabetes Res Clin Pract. 2010;89:126–33. doi: https://doi.org/10.1016/j.diabres.2010.05.012Zoungas S, Chalmers J, Kengne AP, et al. The efficacy of lowering glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial. Diabetes Res Clin Pract. 2010;89:126–33. doi: https://doi.org/10.1016/j.diabres.2010.05.012Ida S, Kaneko R, Murata K. Effects of oral antidiabetic drugs on left ventricular mass in patients with type 2 diabetes mellitus: a network meta-analysis. Cardiovasc Diabetol. 2018;17:129. doi: https://doi.org/10.1186/s12933-018-0773-1Ida S, Kaneko R, Murata K. Effects of oral antidiabetic drugs on left ventricular mass in patients with type 2 diabetes mellitus: a network meta-analysis. Cardiovasc Diabetol. 2018;17:129. doi: https://doi.org/10.1186/s12933-018-0773-1Pirart J, Lauvaux JP, Rey W. Blood sugar and diabetic complications. N Engl J Med. 1978;298(20):1149. doi: https://doi.org/10.1056/NEJM197805182982020Pirart J, Lauvaux JP, Rey W. Blood sugar and diabetic complications. N Engl J Med. 1978;298(20):1149. doi: https://doi.org/10.1056/NEJM197805182982020Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-1589. doi: https://doi.org/10.1056/NEJMoa0806470Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-1589. doi: https://doi.org/10.1056/NEJMoa0806470Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643-2653. doi: https://doi.org/10.1056/NEJMoa052187Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643-2653. doi: https://doi.org/10.1056/NEJMoa052187ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-2572. doi: https://doi.org/10.1056/NEJMoa0802987ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-2572. doi: https://doi.org/10.1056/NEJMoa0802987Mohan V, Khunti K, Chan SP, et al. Management of type 2 diabetes in developing countries: balancing optimal glycaemic control and outcomes with affordability and accessibility to treatment. Diabetes Ther. 2020;11(1):15−35. doi: https://doi.org/10.1007/s13300-019-00733-9Mohan V, Khunti K, Chan SP, et al. Management of type 2 diabetes in developing countries: balancing optimal glycaemic control and outcomes with affordability and accessibility to treatment. Diabetes Ther. 2020;11(1):15−35. doi: https://doi.org/10.1007/s13300-019-00733-9Zoungas S, Chalmers J, Neal B, et al. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med. 2014;371(15):1392-1406. doi: https://doi.org/10.1056/NEJMoa1407963Zoungas S, Chalmers J, Neal B, et al. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med. 2014;371(15):1392-1406. doi: https://doi.org/10.1056/NEJMoa1407963Chalmers J, Woodward M. Observational analyses from ADVANCE and ADVANCE-ON. Diabetes Obes Metab. 2020;22(2):19-32. doi: https://doi.org/10.1111/dom.13894Chalmers J, Woodward M. Observational analyses from ADVANCE and ADVANCE-ON. Diabetes Obes Metab. 2020;22(2):19-32. doi: https://doi.org/10.1111/dom.13894Wong MG, Perkovic V, Chalmers J, et al. Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON. Diabetes Care. 2016;39:694–700. doi: https://doi.org/10.2337/dc15-2322Wong MG, Perkovic V, Chalmers J, et al. Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON. Diabetes Care. 2016;39:694–700. doi: https://doi.org/10.2337/dc15-2322Maloney A, Rosenstock J, Fonseca V. A Model-Based Meta-Analysis of 24 Antihyperglycemic Drugs for Type 2 Diabetes: Comparison of Treatment Effects at Therapeutic Doses. Clin Pharmacol Ther. 2019;105(5):1213-23. doi: https://doi.org/10.1002/cpt.1307Maloney A, Rosenstock J, Fonseca V. A Model-Based Meta-Analysis of 24 Antihyperglycemic Drugs for Type 2 Diabetes: Comparison of Treatment Effects at Therapeutic Doses. Clin Pharmacol Ther. 2019;105(5):1213-23. doi: https://doi.org/10.1002/cpt.1307Al Sifri S, Basiounny A, Echtay A, et al. The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a ran- domised trial. Int J Clin Pract. 2011;65:1132–40. doi: https://doi.org/10.1111/j.1742-1241.2011.02797.xAl Sifri S, Basiounny A, Echtay A, et al. The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a ran- domised trial. Int J Clin Pract. 2011;65:1132–40. doi: https://doi.org/10.1111/j.1742-1241.2011.02797.xTayek J. SUR receptor activity vs. incidence of hypoglycaemia and cardiovascular mortality with sulphonylurea therapy for diabetics. Diabetes Obes Metab. 2008;10(11):1128-9;1129-30. doi: https://doi.org/10.1111/j.1463-1326.2008.00928.xTayek J. SUR receptor activity vs. incidence of hypoglycaemia and cardiovascular mortality with sulphonylurea therapy for diabetics. Diabetes Obes Metab. 2008;10(11):1128-9;1129-30. doi: https://doi.org/10.1111/j.1463-1326.2008.00928.xSchernthaner G, Grimaldi A, Di Mario U, Drzewoski J, et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest. 2004;34(8):535-42. doi: https://doi.org/10.1111/j.1365-2362.2004.01381.xSchernthaner G, Grimaldi A, Di Mario U, Drzewoski J, et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest. 2004;34(8):535-42. doi: https://doi.org/10.1111/j.1365-2362.2004.01381.xHassanein M, Al Sifri S, Shaikh S, et al. A real-world study in patients with type 2 diabetes mellitus treated with gliclazide modified-release during fasting: DIA-RAMADAN. Diabetes Res Clin Pract. 2020;163:108154. doi: https://doi.org/10.1016/j.diabres.2020.108154Hassanein M, Al Sifri S, Shaikh S, et al. A real-world study in patients with type 2 diabetes mellitus treated with gliclazide modified-release during fasting: DIA-RAMADAN. Diabetes Res Clin Pract. 2020;163:108154. doi: https://doi.org/10.1016/j.diabres.2020.108154Kalra S, Bahendeka S, Sahay R, et al. Consensus Recommendations on Sulfonylurea and Sulfonylurea Combinations in the Management of Type 2 Diabetes Mellitus — International Task Force. Indian J Endocrinol Metab. 2018;22(1):132-157. doi: https://doi.org/10.4103/ijem.IJEM_556_17Kalra S, Bahendeka S, Sahay R, et al. Consensus Recommendations on Sulfonylurea and Sulfonylurea Combinations in the Management of Type 2 Diabetes Mellitus — International Task Force. Indian J Endocrinol Metab. 2018;22(1):132-157. doi: https://doi.org/10.4103/ijem.IJEM_556_17Lee YH, Lee CJ, Lee HS, et al. Comparing kidney outcomes in type 2 diabetes treated with different sulphonylureas in real-life clinical practice. Diabetes Metab. 2015;41(3):208-15. doi: https://doi.org/10.1016/j.diabet.2015.01.004Lee YH, Lee CJ, Lee HS, et al. Comparing kidney outcomes in type 2 diabetes treated with different sulphonylureas in real-life clinical practice. Diabetes Metab. 2015;41(3):208-15. doi: https://doi.org/10.1016/j.diabet.2015.01.004Pearson ER, Starkey BJ, Powell RJ, et al. Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet. 2003;362(9392):1275-81. doi: https://doi.org/10.1016/S0140-6736(03)14571-0Pearson ER, Starkey BJ, Powell RJ, et al. Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet. 2003;362(9392):1275-81. doi: https://doi.org/10.1016/S0140-6736(03)14571-0Roberts A, James J, Dhatariya K; Joint British Diabetes Societies (JBDS) for Inpatient Care. Management of hyperglycaemia and steroid (glucocorticoid) therapy: a guideline from the Joint British Diabetes Societies (JBDS) for Inpatient Care group. Diabet Med. 2018;35(8):1011-1017. doi: https://doi.org/10.1111/dme.13675Roberts A, James J, Dhatariya K; Joint British Diabetes Societies (JBDS) for Inpatient Care. Management of hyperglycaemia and steroid (glucocorticoid) therapy: a guideline from the Joint British Diabetes Societies (JBDS) for Inpatient Care group. Diabet Med. 2018;35(8):1011-1017. doi: https://doi.org/10.1111/dme.13675Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022;65(12):1925-1966. doi: https://doi.org/10.1007/s00125-022-05787-2Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022;65(12):1925-1966. doi: https://doi.org/10.1007/s00125-022-05787-2Marx N, Federici M, Schütt K, et al.; ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 202;44(39):4043-4140. doi: https://doi.org/10.1093/eurheartj/ehad192Marx N, Federici M, Schütt K, et al.; ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 202;44(39):4043-4140. doi: https://doi.org/10.1093/eurheartj/ehad192Seino S, Zhang CL, Shibasaki T. Sulfonylurea action re-revisited. J Diabetes Investig. 2010;1(1-2):37-9. doi: https://doi.org/10.1111/j.2040-1124.2010.00014.xSeino S, Zhang CL, Shibasaki T. Sulfonylurea action re-revisited. J Diabetes Investig. 2010;1(1-2):37-9. doi: https://doi.org/10.1111/j.2040-1124.2010.00014.x

The authors declare that there are no conflicts of interest present.